[go: up one dir, main page]

CL2019000174A1 - Composición vaginal que comprende una combinación de estrógeno y vitamina d. - Google Patents

Composición vaginal que comprende una combinación de estrógeno y vitamina d.

Info

Publication number
CL2019000174A1
CL2019000174A1 CL2019000174A CL2019000174A CL2019000174A1 CL 2019000174 A1 CL2019000174 A1 CL 2019000174A1 CL 2019000174 A CL2019000174 A CL 2019000174A CL 2019000174 A CL2019000174 A CL 2019000174A CL 2019000174 A1 CL2019000174 A1 CL 2019000174A1
Authority
CL
Chile
Prior art keywords
vitamin
estrogen
combination
vaginal composition
analog
Prior art date
Application number
CL2019000174A
Other languages
English (en)
Inventor
Enrico Colli
David F Archer
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of CL2019000174A1 publication Critical patent/CL2019000174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA COMPOSICIÓN VAGINAL QUE COMPRENDE UNA COMBINACIÓN DE ESTRÓGENO Y VITAMINA-D O UN ANÁLOGO DE VITAMINA-D EN UNA DOSIS DIARIA DE (I) ESTRÓGENO QUE CORRESPONDE A 1 µG A 100 µG DE ESTRÓGENO EQUIVALENTE DE ESTRADIOL Y (II) VITAMINA-D O ANÁLOGO QUE CORRESPONDE A DESDE 7,5 µG A 100 µG DE VITAMINA-D EQUIVALENTE.
CL2019000174A 2016-07-22 2019-01-22 Composición vaginal que comprende una combinación de estrógeno y vitamina d. CL2019000174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305941.3A EP3272333A1 (en) 2016-07-22 2016-07-22 Vaginal composition comprising a combination of estrogen and vitamin d

Publications (1)

Publication Number Publication Date
CL2019000174A1 true CL2019000174A1 (es) 2019-06-28

Family

ID=56561320

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000174A CL2019000174A1 (es) 2016-07-22 2019-01-22 Composición vaginal que comprende una combinación de estrógeno y vitamina d.

Country Status (10)

Country Link
US (2) US20190224213A1 (es)
EP (2) EP3272333A1 (es)
BR (1) BR112019001207A2 (es)
CL (1) CL2019000174A1 (es)
CO (1) CO2019000604A2 (es)
CR (1) CR20190026A (es)
MX (1) MX390231B (es)
NI (1) NI201900004A (es)
PH (1) PH12019500137A1 (es)
WO (1) WO2018015503A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN112135621A (zh) * 2018-05-04 2020-12-25 宝洁公司 用于治疗阴道萎缩的组合物和方法
EP3787656A1 (en) 2018-05-04 2021-03-10 The Procter & Gamble Company Compositions and methods for treating vaginal dryness
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4066824A1 (en) * 2021-03-31 2022-10-05 Dompe' Farmaceutici S.P.A. Combination therapy for covid-19 vaccination

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5514698A (en) 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
JP3705620B2 (ja) 1994-12-28 2005-10-12 帝国臓器製薬株式会社 経粘膜投与用製剤
WO1997031631A1 (en) 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
TW358031B (en) 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US20040043071A1 (en) 2002-06-21 2004-03-04 Pauletti Giovanni M. Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
FR2766710B1 (fr) 1997-08-04 1999-10-29 Inst Pharma De Rech Applic Et Composition pharmaceutique, comprime forme a partir de celle-ci et son utilisation comme antiseptique vaginal a action prolongee
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
JP4851057B2 (ja) 2000-12-15 2012-01-11 ノボ・ノルディスク・フェムケア・アーゲー 萎縮性膣炎の治療のためのエストロゲンを含有する組成物の製造におけるエストロゲンの使用
US7004171B2 (en) 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
WO2004103232A1 (en) 2003-05-15 2004-12-02 Apothecus Pharmaceutical Corp. Dissolvable vaginal deodorizing films and methods of vaginal deodorizing utilizing pliable dissolvable film
JP2007502823A (ja) 2003-08-15 2007-02-15 キューエルティー・ユーエスエイ・インコーポレーテッド 接着性および生体侵食性の経粘膜薬物送達システム
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
US20060040904A1 (en) 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
CN101175503B (zh) 2005-04-27 2012-12-12 深圳福诺生物技术有限公司 一种调节并保持阴道菌群和阴道酸度正常的组合物与方法
EP1983999A4 (en) 2006-01-27 2010-10-20 Teva Womens Health Inc COURSES FOR THE TREATMENT OF ECOLOGICAL DISEASES
US20110159091A1 (en) 2007-05-24 2011-06-30 Alan Stone Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US20080312198A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
ES2626156T3 (es) 2009-07-21 2017-07-24 The Population Council, Inc. Anillo vaginal de gradiente multicapa
MX2013002016A (es) 2010-08-20 2013-03-25 Teva Womens Health Inc Dispositivos intravaginales, metodos de fabricacion y usos de los mismos.
CN102641548B (zh) 2011-02-18 2016-08-03 帕洛阿尔托研究中心公司 包括化学品渗透增强剂的透粘膜药物输送装置和方法
CN104203169B (zh) 2011-12-29 2016-07-13 安德罗玛克实验室股份有限公司 包含美洛昔康和调节所述活性成分的释放的试剂的阴道环，其可用作在女性中连续使用的避孕药
JP5887424B2 (ja) 2011-12-29 2016-03-16 ウニベルシダッド デ チリ Ｄｈｅａまたは硫酸ｄｈｅａを有し、かつ有効成分の放出調節薬を任意に有し、女性における卵巣予備能を増やし、かつ閉経期に関連する症状を緩和する膣リング
ITMI20120867A1 (it) 2012-05-18 2013-11-19 Labomar S R L Composizione per il trattamento di lesioni.
FR3018193B1 (fr) 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
SG11201607600TA (en) * 2014-03-13 2016-10-28 Singapore Ze&Z Internat Pte Ltd Vaginal composition and use thereof
WO2016054002A1 (en) 2014-09-29 2016-04-07 Yale University Progesterone impregnated vaginal ring/pessary

Also Published As

Publication number Publication date
PH12019500137A1 (en) 2019-07-29
US20210069210A1 (en) 2021-03-11
CR20190026A (es) 2019-04-09
MX2019000806A (es) 2019-06-20
WO2018015503A1 (en) 2018-01-25
EP3487478A1 (en) 2019-05-29
MX390231B (es) 2025-03-20
US11590145B2 (en) 2023-02-28
US20190224213A1 (en) 2019-07-25
NI201900004A (es) 2019-04-29
BR112019001207A2 (pt) 2019-04-30
CO2019000604A2 (es) 2019-05-21
EP3272333A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
MX2017008698A (es) Composiciones multi-suplementos.
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CO2019001043A2 (es) Composición de cannabis
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX2016006025A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
MX2018000021A (es) Composiciones multifasicas.
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.